Signal: Fresh Tracks nears end of operations with plans for dissolution

Preview

来源: Pharmaceutical Technology

Judith Oke

Preview

来源: Pharmaceutical Technology

Fresh Tracks is planning to seek approval for liquidation and dissolution from stakeholders pending a better offer. Image credit: Andrii Yalanskyi/Shutterstock

Fresh Tracks Therapeutics has announced a proposed dissolution and liquidation of the company in “an orderly fashion” as stated by Andrew Sklawer, President and CEO of Fresh Tracks. Following the report on 19 September, Fresh Tracks stocks witnessed a 53.4% increase on market open of 20 September compared to market close on the 19th, with a market cap of $5.292m.

The board agreed to this after multiple attempts to save the biopharma company through mergers, asset sales and financing without success. With the present development, Fresh Tracks is shutting down all clinical and preclinical development programs, and laying off most of its employees by early October leaving out key members of staff to complete the company’s dissolution. In addition, it will file a certificate of dissolution and a delisting from Nasdaq.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - PVT-REMOVE GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - TED-N in Paralysis GlobalData

View allCompanies IntelligenceAPA CorpFresh Tracks Therapeutics IncBotanix Pharmaceuticals LtdView all

The biopharma is also planning to meet with shareholders in the fourth quarter of this year to seek liquidation and dissolution approval, after which all remaining cash will be distributed to shareholders. Liquidating distributions will be made based on outstanding shares (5,926,497 shares of common stock) as of 19 September 2023 at an aggregate amount of between $5m and $7m, or $0.84 and $1.17 per share.

The news follows the amendment of its Asset Purchase Agreement (APA) with Botanix Pharmaceuticals and Botanix SB after the sales of sofpironium bromide, which the CEO of Fresh Tracks thought would strengthen their financial position at the time.

The company’s assets under development include FRTX-02 for autoimmune diseases currently in Phase I stage 2, FRTX-10 (indicated for autoinflammatory diseases) and FRTX-03 in preclinical stages and another in discovery phase.

Fresh Tracks has stated that although it has plans to shut down operations, it will change its mind if it receives an offer of superior value to its shareholders.

Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。